SR33805是一种有效的Ca2+通道拮抗剂，在去极化和极化条件下的EC50值分别为4.1nM和33nM。SR33805阻止L型而不是T型Ca2+通道。SR33805可用于研究急性或慢性心脏衰竭。
| Cas No. | 121345-64-0 |
| Canonical SMILES | O=S(C1=CC=C(OCCCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1)(C3=C(C(C)C)N(C)C4=C3C=CC=C4)=O |
| 分子式 | C32H40N2O5S |
| 分子量 | 564.74 |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts[1][2]. SR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.20SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats[2].SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs[3]. Animal Model: Male Wistar rats (5 weeks) are subjected to coronary artery ligature[2] [1]. Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263(1-2): 101-5.
[2]. Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9.
[3]. Hainaud P, et, al. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1; 154(2): 301-8. |
